Compare AbCellera Biologics Inc (ABCL) vs Sezzle Inc (SEZL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Sezzle Inc — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while Sezzle Inc trades at $167.09 (market cap $5.97B). The key difference: Sezzle Inc is far larger — about 2.5× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | SEZL | |
|---|---|---|
Market Cap | $2.35B | $5.97B |
Sector | Health | Technology |
52-Week High | $8.12 | $183.24 |
52-Week Low | $2.78 | $50.97 |
Enterprise Value | $1.99B | $6.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Sezzle (SEZL) trades at $179.05, down 2.29% today, but maintains a strong bullish technical trend with moving averages supporting further upside. Fundamentally, the company exhibits robust profitability with a 30.83% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights product expansion and strong Q1 2026 results, driving positive sentiment.
The outlook remains positive given accelerating revenue growth and raised guidance, though risks include potential securities litigation and high valuation multiples. Analysts are predominantly bullish with a consensus price target of $146.40, suggesting caution near-term, but operational momentum supports long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
